Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 6, 2011, Pages 2593-2598

  Kannan, Pavitra ^a,b   Brimacombe, Kyle R ^c   Kreisl, William C ^a   Liow, Jeih San ^a   Zoghbi, Sami S ^a   Telu, Sanjay ^a   Zhang, Yi ^a   Pike, Victor W ^a   Halldin, Christer ^b   Gottesman, Michael M ^c   Innis, Robert B ^a   Hall, Matthew D ^c  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

ATP binding cassette; Efflux

Indexed keywords

CHLOROQUINE; GLYCOPROTEIN P; N DESMETHYL LOPERAMIDE C 11; PACLITAXEL; RADIOPHARMACEUTICAL AGENT; TARIQUIDAR; UNCLASSIFIED DRUG;

ACIDITY; ALKALINITY; ANIMAL EXPERIMENT; ARTICLE; BLADDER; BLOOD BRAIN BARRIER; BRAIN; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG PENETRATION; DRUG UPTAKE; GALLBLADDER; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; ION TRANSPORT; ISOTOPE LABELING; KIDNEY; LIVER ABSCESS; LYSOSOME; MOLECULAR INTERACTION; MOLECULAR MECHANICS; MOUSE; MUSCLE; NONHUMAN; NORMAL HUMAN; OPTICAL TWEEZERS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTON TRANSPORT; RADIOACTIVITY; SPLEEN;

ANIMALS; BLOOD-BRAIN BARRIER; CELL LINE, TUMOR; HUMANS; ISOTOPE LABELING; LOPERAMIDE; LYSOSOMES; MICE; P-GLYCOPROTEIN; POSITRON-EMISSION TOMOGRAPHY; QUINOLINES; TRITIUM;

MUS;

EID: 79952307217     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1014641108     Document Type: Article

References (35)

1. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2:48-58. (Pubitemid 37328807)
2. Löscher W, Potschka H (2005) Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 76:22-76. (Pubitemid 41033402)
3. Kannan P, et al. (2010) N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier. Drug Metab Dispos 38:917-922.
4. 11C-N-desmethyl-loperamide. J Nucl Med 51:559-566.
5. 11C]N-desmethylloperamide as a new and improved PET radiotracer for imaging P-gp function. J Med Chem 51:6034-6043.
6. 11C-N-desmethyl-loperamide in monkeys. J Nucl Med 50:108-115.
7. Castell F, Cook GJ (2008) Quantitative techniques in 18FDG PET scanning in oncology. Br J Cancer 98:1597-1601. (Pubitemid 351684676)
8. de Duve C, et al. (1974) Commentary. Lysosomotropic agents. Biochem Pharmacol 23:2495-2531.
9. Sykes P, ed (1988) A Guidebook to Mechanism in Organic Chemistry (Longman, London), 6th ed.
10. Kaufmann AM, Krise JP (2007) Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications. J Pharm Sci 96:729-746. (Pubitemid 46657864)
11. MacIntyre AC, Cutler DJ (1988) The potential role of lysosomes in tissue distribution of weak bases. Biopharm Drug Dispos 9:513-526.
12. Altan N, Chen Y, Schindler M, Simon SM (1999) Tamoxifen inhibits acidification in cells independent of the estrogen receptor. Proc Natl Acad Sci USA 96:4432-4437. (Pubitemid 29190353)
13. Agostinelli E, Seiler N (2007) Lysosomotropic compounds and spermine enzymatic oxidation products in cancer therapy (review). Int J Oncol 31:473-484.
14. Sauna ZE, Nandigama K, Ambudkar SV (2006) Exploiting reaction intermediates of the ATPase reaction to elucidate the mechanism of transport by P-glycoprotein (ABCB1). J Biol Chem 281:26501-26511. (Pubitemid 44401859)
15. Pfister JR, et al. (1995) Methanodibenzosuberylpiperazines as potent multidrug resistance reversal agents. Bioorg Med Chem Lett 5:2473-2476.
16. Barranco WT, Eckhert CD (2006) Cellular changes in boric acid-treated DU-145 prostate cancer cells. Br J Cancer 94:884-890.
17. Schindler M, Grabski S, Hoff E, Simon SM (1996) Defective pH regulation of acidic compartments in human breast cancer cells (MCF-7) is normalized in adriamycin-resistant cells (MCF-7adr). Biochemistry 35:2811-2817.
18. Willingham MC, Cornwell MM, Cardarelli CO, Gottesman MM, Pastan I (1986) Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: effects of verapamil and other drugs. Cancer Res 46:5941-5946. (Pubitemid 17178008)
19. Moriyama Y, Manabe T, Yoshimori T, Tashiro Y, Futai M (1994) ATP-dependent uptake of anti-neoplastic agents by acidic organelles. J Biochem 115:213-218. (Pubitemid 24060150)
20. Okabe M, et al. (2008) Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther 7:3081-3091.
21. Koponen M, Grieder A, Hauser R, Loor F (1985) Interference of cyclosporin with lymphocyte proliferation: Effects on mitochondria and lysosomes of cyclosporin-sensitive or -resistant cell clones. Cell Immunol 93:486-496. (Pubitemid 15235134)
22. Millot C, Millot JM, Morjani H, Desplaces A, Manfait M (1997) Characterization of acidic vesicles in multidrug-resistant and sensitive cancer cells by acridine orange staining and confocal microspectrofluorometry. J Histochem Cytochem 45:1255-1264. (Pubitemid 27392333)
23. Ndolo RA, Forrest ML, Krise JP (2010) The role of lysosomes in limiting drug toxicity in mice. J Pharmacol Exp Ther 333:120-128.
24. Kannan P, et al. (2010) The "specific" P-glycoprotein inhibitor tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). ACS Chem Neurosci, 10.1021/cn100078a.
25. 11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor. Bioorg Med Chem 18:5489-5497.
26. 11C]XR9576 to assess the function of drug efflux transporters using PET. Ann Nucl Med 24:403-412.
27. Fox E, Bates SE (2007) Tariquidar (XR9576): A P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther 7:447-459. (Pubitemid 46681800)
28. Kannan P, et al. (2009) Imaging the function of P-glycoprotein with radiotracers: Pharmacokinetics and in vivo applications. Clin Pharmacol Ther 86:368-377.
29. 11C-verapamil transfer at the human blood-brain barrier for evaluation of P-glycoprotein function. J Nucl Med 47:1531-1537.
30. Piwnica-Worms D, Sharma V (2010) Probing multidrug resistance P-glycoprotein transporter activity with SPECT radiopharmaceuticals. Curr Top Med Chem 10:1834-1845.
31. Hendrikse NH, et al. (1998) 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. Br J Cancer 77:353-358. (Pubitemid 28044036)
32. Sharma V, Prior JL, Belinsky MG, Kruh GD, Piwnica-Worms D (2005) Characterization of a 67Ga/68Ga radiopharmaceutical for SPECT and PET of MDR1 P-glycoprotein transport activity in vivo: Validation in multidrug-resistant tumors and at the blood-brain barrier. J Nucl Med 46:354-364. (Pubitemid 43073447)
33. Zoghbi SS, et al. (2008) 11C-loperamide and its N-desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux. J Nucl Med 49:649-656. (Pubitemid 351520614)
34. Vogelgesang S, et al. (2002) Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 12:535-541. (Pubitemid 35177083)
35. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Ser B 57:289-300.